# A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in COVID-19 Patients With Acute Pulmonary Hypertension

> **NCT04885491** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Attgeno AB**

## Conditions studied

- Pulmonary Hypertension
- COVID-19

## Interventions

- **DRUG:** Sodium chloride (placebo)
- **DRUG:** PDNO

## Key facts

- **NCT ID:** NCT04885491
- **Lead sponsor:** Attgeno AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-05-07
- **Primary completion:** 2023-04-30
- **Final completion:** 2023-04-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Since the availability of vaccines, a drastic drop in number of patients with increased PAP was observed and when the WHO re-categorized the COVID-19 pandemic from PHEIC to an "established and ongoing health issue" the study was withdrawn.
- **Last updated:** 2023-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04885491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04885491, "A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in COVID-19 Patients With Acute Pulmonary Hypertension". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04885491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*